Philips to Further Roll Out RATE: AI for Early Infection Detection at U.S. Department of Defense Through Four-Year, $25 Million Contract
29 Outubro 2024 - 9:06AM
Business Wire
After successful development and pilot, groundbreaking
technology using biomarkers from wearables to predict infection is
set to expand within the DoD
Royal Philips (NYSE: PHG, AEX: PHIA) today announced it
will accelerate the predictive health monitoring of the Rapid
Analysis of Threat Exposure (RATE) algorithm to support the
well-being and readiness of active-duty service personnel for the
U.S. Department of Defense (DoD). Over the next four years, the
Joint Program Executive Office for Chemical, Biological,
Radiological and Nuclear Defense (JPEO-CBRND), will invest $25
million to make the technology more accessible in the field.
RATE, in advanced development, is an early detector of
pre-symptomatic infection in humans. It is part of efforts to
improve the readiness monitoring of active-duty personnel and has
broad application in healthcare settings. The algorithm was
developed as an early warning system that can reduce an
individual’s downtime and aid in quickly containing the spread of
disease by allowing exposed individuals to self-isolate or seek
medical attention sooner.
“Our mission is to protect our troops and ensure we can quickly
detect and prevent the spread of illness that can impact their
wellbeing and our ability to protect our nation,” said Lorenzo
Hankla, JPEO Wearables Program Officer. “Giving them the option of
using readily available off-the-shelf wearables that are trained on
clinical data allows them to passively monitor their health and
quickly act if their infection score is high. In the wake of the
pandemic, our troops need access to new AI-enabled technologies
that can have a meaningful impact on their readiness and ensure
overall military operations.”
The first version of the RATE algorithm, developed in 2019, used
large-scale data science, machine learning, and trade-space
analyses across demographics and 163 different biomarkers (vital
signs and laboratory measurements) from a rich Philips data set of
over 36,000 cases of hospital-acquired infections to develop a risk
score. The risk score worked for multiple general types of
infection, including common respiratory infections like
pneumococcal pneumonia. These results were published in a 2023
study in Frontiers in Medicine.
A wearable version of the algorithm, prompted by the COVID-19
pandemic, leveraged biometric data from commercial-off-the-shelf
wearables to enable early detection of infection. A 2022 study
published in Nature’s Scientific Reports showed how, in a
cohort of 9,381 DoD personnel, the algorithm was able to detect
COVID-19 infection on average 2.3 days before symptoms appeared and
up to six days prior. The study highlighted the utilization of
algorithm-powered wearables to aid military readiness.
“Protecting the physical health and well-being of active service
members is paramount,” said Jeff DiLullo, Chief Region Leader,
Philips North America, and U.S. Army Veteran. “Our military
personnel have unique care needs depending on their role and
environment, and thanks to AI-enabled, predictive innovations like
RATE, we can enable more timely intervention and personalized care,
reducing downtime and improving outcomes – not only for individuals
but entire units, too. The faster we diagnose and treat, the sooner
these brave men and women are ready for duty.”
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being through meaningful innovation. Philips’ patient- and
people-centric innovation leverages advanced technology and deep
clinical and consumer insights to deliver personal health solutions
for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, ultrasound, image-guided therapy, monitoring
and enterprise informatics, as well as in personal health. Philips
generated 2023 sales of EUR 18.2 billion and employs approximately
69,300 employees with sales and services in more than 100
countries. News about Philips can be found at
www.philips.com/newscenter.
About the JPEO-CBRND:
The Joint Program Executive Office for Chemical, Biological,
Radiological and Nuclear Defense (JPEO-CBRND) mission is to provide
an integrated layered chemical, biological, radiological, and
nuclear defense capabilities to the joint force across combined
Joint All-Domain Operations. JPEO-CBRND’s goal is to enable the
joint force to fight and win unencumbered by a CBRN environment. To
learn more about JPEO-CBRND, visit: https://www.jpeocbrnd.osd.mil/,
or follow JPEO-CBRND on social media @JPEOCBRND.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241029182852/en/
Silvie Casanova Philips North America Tel: +1-781-879-0692
Email: silvie.casanova@philips.com
Avi Dines Philips North America Tel: +1-781 690 3814 Email:
avi.dines@philips.com
Koninklijke Philips NV (NYSE:PHG)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Koninklijke Philips NV (NYSE:PHG)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024